Medicine Overview

Indication

Know Medicine, Follow Guideline

Adult Dose

Clinical InformationAdministration Information
Indication: Chronic Hepatitis C
Condition: Genotypes 1, 4, 5, or 6
Dose: Subcutaneous injection – 1.5 mcg/kg
Frequency: once weekly
Duration: 12 weeks (treatment-naive or relapsed); may extend to 24 weeks for nonresponders
Note: Not to exceed 150 mcg/week; part of preferred regimen PLUS Ribavirin by mouth 1000-1200 mg/day plus sofosbuvir 400 mg by mouth once daily; Peginterferon is not recommended as monotherapy for any patient group
Indication: Chronic Hepatitis C
Condition: Genotype 1
Dose: Tablet – Simeprevir 150 mg/day plus Peginterferon/Ribavirin
Duration: Simeprevir for 12 weeks plus Peginterferon/Ribavirin for 24 weeks
Note: Alternative regimen

Child Dose

Clinical InformationAdministration Information
Indication: Chronic Hepatitis C
Age: less than 3 years
Dose: Subcutaneous Injection – Safety and efficacy not established
Note: Safety and efficacy not established
Indication: Chronic Hepatitis C
Age: 3-17 years
Dose: Subcutaneous Injection – 60 mcg/m²
Frequency: once weekly
Note: administered with ribavirin 15 mg/kg/day by mouth divided every 12 hours; administer on same day each week

Renal Dose

Clinical InformationAdministration Information
Indication: chronic hepatitis C
Condition: moderate renal impairment (CrCl 30-50 mL/min)
Dose: alpha interferons
Note: Reduce dose by 25%
Indication: chronic hepatitis C
Condition: severe renal impairment (CrCl 10-29 mL/min, including hemodialysis)
Dose: alpha interferons
Note: Reduce dose by 50%
Administration
  • Inject subcutaneously once weekly
  • Rotate injection sites
Side Effect

Drug Interaction

Drug NameRisk Factors
Ribavirin
Increased risk of haemolytic anemia, birth defects and/or foetal mortality, genotoxicity, mutagenicity, and may possibly be carcinogenic
Theophylline
Decreases metabolism

Disease Interaction

Disease NameRisk Factors
Autoimmune hepatitis
May worsen liver condition
Decompensated liver disease
Risk of liver failure

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage

Details coming soon

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.